OCEAN Dx is completing the industrialization of its sepsis test and plans clinical trials in 2026, targeting CE marking. OCEAN Dx will launch its rapid sepsis diagnostic test in Europe by 2029.

A rapid diagnostic test from Ocean Dx SAS delivered gold standard performance in a clinical evaluation that points to a potential shift in how sepsis is identified and treated. The assay, which ...

Inmates with a history of drug use are at particular risk of dying from untreated sepsis in US prisons and jails, USA TODAY ...

C-reactive protein (CRP) is a widely used biomarker for sepsis evaluation in newborns. However, although it has a high ...

ABIONYX Pharma, (FR0012616852 - ABNX - eligible PEA PME), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I-based ...

NHS Scotland is the first in the UK to introduce nationwide genetic testing for newborns with suspected infection.

A new discovery from the lab of YouYang Zhao, Ph.D., from Stanley Manne Children's Research Institute at Ann & Robert H.

ACTON, Mass. - Bluejay Diagnostics, Inc. (NASDAQ:BJDX) announced Monday that patient enrollment in its SYMON-II pivotal clinical trial has reached approximately 50% completion, as the company ...

For years, the approach to sepsis in acute care settings has been the same: early warning alerts and standardized care protocols. Unfortunately, it hasn’t moved the needle. Sepsis still affects 2.5 ...

The test was piloted and implemented in Manchester and has now been successfully introduced by NHS Greater Glasgow and Clyde ...

A USA TODAY investigation reveals that sepsis from treatable infections is turning deadly for inmates in jails and prisons.